To validate our results in more clinically relevant models, we determined the efficacy of AZD4573 inhibition on 13 patient-derived organoids (PDO) established from PDX tumors of ER+ patient primary or metastatic tumors. Here, ESR1 is linked to metastatic neoplasm.